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Abstract
Acetylcholine challenge produces M3 muscarinic
acetylcholine receptor activation and accessory/
scaffold proteins recruitment into a signalsome
complex. The dynamics of such a complex is not well
understood but a conserved NPxxY motif located
within transmembrane 7 and juxtamembrane helix 8
of the receptor was found to modulate G protein
activation. Here by means of receptor mutagenesis
we unravel the role of the conserved M3 muscarinic
acetylcholine receptor NPxxY motif on ligand binding,
signaling and multiprotein complex formation.
Interestingly, while a N7.49D receptor mutant showed
normal ligand binding properties a N7.49A mutant had
reduced antagonist binding and increased affinity for
carbachol. Also, besides this last mutant was able to
physically couple to Gαq/11 after carbachol challenge
it was neither capable to activate phospholipase C
nor phospholipase D. On the other hand, we
demonstrated that the Asn-7.49 is important for the
interaction between M3R and ARF1 and also for the
formation of the ARF/Rho/βγ signaling complex, a
complex that might determine the rapid activation and
desensitization of PLD. Overall, these results indicate
that the NPxxY motif of the M3 muscarinic acetylcholine
receptor acts as key conformational switch for
receptor signaling and multiprotein complex formation.
Introduction
The M3 muscarinic acetylcholine receptor (M3R) is
a member of the muscarinic receptor family that controls
a large array of functions in both the central and peripheral
nervous systems [1]. It is a class A, rhodopsin-like, G
protein-coupled receptor (GPCR) that signals through the
heterotrimeric G protein Gαq/11, thus activating
phospholipase Cβ (PLCβ) and increasing intracellular
calcium [2]. M3R regulates a network of signaling
molecules, including protein kinase C (PKC), small Rho
GTPase, phospholipase D (PLD), phosphoinositide-3
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kinase (PI3K), non-receptor kinases and mitogen-
activated protein kinases (MAPKs) [3].
Interactions within conserved residues in the M3R
intracellular loops have been proposed to be critical in
preserving normal receptor activation, G protein-coupling,
signaling and trafficking [4-6]. Chimeric receptor
construction together with site directed mutagenesis
showed that both the M3R second intracellular loop and
the C-terminal portion of the third intracellular loop are
important for coupling to the Gαq/11 protein [7]. In addition,
receptor activation is mediated by a conformational
rearrangement that includes transmembrane helix 7
(TMH7) and probably, as described for rhodopsin,
movement within the C terminal tail juxtamembrane helix
8 (HX8) [8].
Sequence alignment of GPCRs of the rhodopsin
subfamily reveals that most members of this subfamily,
including the M3R, contain a widely conserved NPxxY
sequence motif at the end of TMH7 [9]. Interestingly, by
means of mutagenesis and molecular modeling studies
based on the rhodopsin crystal structure it has been shown
that this motif is involved in an interaction network that
modulates receptor’s expression, signaling and trafficking
[10-14]. Also, based on computational studies a theoretical
model that explains the special structural features of the
conserved N/DP motif has been proposed. Hence, this
motif differs from a regular proline kink (of an ideal α-
helix), thus allowing for a major flexibility in the TMH7
[15]. Consequently, by acting as a sensitive conforma-
tional switch this NPxxY motif may play a key role in the
GPCR activation selectivity and efficacy, thus determining
the receptor signaling extend. In addition, this domain
regulates the interaction of the receptor with accessory/
scaffold proteins, thus controling the formation of the
receptor signalosome. Indeed, interaction between M3R
and small monomeric G proteins, for instance ADP-
ribosylation factors (ARFs) and Ras homolog gene family
member A (RhoA), has been described as critical during
the activation of the PLD and ROCK pathway [16-19].
Thus, based on the fact that NPxxY motif is involved in
the activation and signalsome complex formation of some
GPCRs we wanted to know the precise function of this
motif in the M3R. Therefore, two mutants were generated,
namely the Asn at position 540 (N7.49) and located within
the conserved NPxxY motif was replaced by Asp
(N7.49D) and by Ala (N7.49A). Mutation of Asn, to Ala
switches the M3R to a high affinity inactive conformation
unable to signal properly. However, the mutated receptor
keeps the ability to form stable complexes with Gαq/11
protein in response to agonist-stimulation, as demonstrated
by means of co-immunoprecipitation experiments. On the
other hand, the N7.49D mutant (M3RN7.49D) showed a
unlike activation time-course and desensitization profile
when compared to the M3Rwt. Also, by means of co-
immunoprecipitation experiments we corroborated that
this mutant uses a non ARF1-mediated pathway to
activate/desensitize the PLD. Overall, we showed that
the conserved Asn residue within the NPxxY motif of
the M3R determines the ability to form stable complexes
with different populations of G proteins (Gαq/11 and
Gα12/13) and small monomeric G proteins (ARF1, ARF6
and RhoA), thus determining the activation/desensitization
profile of the signaling pathways in which this receptor
partake.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium, penicillin/
streptomycin and fetal bovine serum were purchased from
Invitrogen (Carlsbad, CA, USA). [35S]-GTPγS (1,202 Ci/mmol),
[3H]-myo-inositol (3.0 Ci/ml) and N-[3H]-methyl scopolamine
([3H]-NMS, 81 Ci/mmol), were from Amersham Biosciences
(Piscataway, NJ, USA). Restriction enzymes were from New
England Biolabs (Beverly, MA, USA). Carbamylcholine chloride
(carbachol, CCh), atropine sulphate and all other reagents were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Plasmid constructs
The constructs presented here were made using standard
molecular biology techniques employing PCR and fragment
replacement strategy. The cDNAs for the human M3R (kindly
provided by T. Bonner, NIH, USA) was subcloned into the
mammalian expression vector pcDNA-3.1 (Invitrogen)
containing three hemagglutinin (HA) epitopes (pcDNA3.1-
3xHA; gift from P. Calvo, SFU, CA, USA), thus resulting in the
pcDNA3.1-3xHA-M3R vectors. Briefly, 1.9-kb fragment
encoding the human M3R was amplified using sense and
antisense primers harboring unique EcoRV and XbaI sites and
then subcloned into EcoRV/XbaI sites of the mammalian
pcDNA3.1-3xHA vector. The Asn of the M3R NPxxY motif was
exchange to Asp and Ala by using the QuikChange site directed
mutagenesis kit from Stratagene (La Jolla, CA, USA). The sense
primers used were: FM3RN7.49D (5’-ACC TCT CTG GCT GTC
CTA CTC ACC-3’); FM3RN7.49A (5’-CTG TTT CTG CTG GGC
CCC CGC CTT TG-3’). The cDNA encoding the human GPR37
receptor was purchased from GenomeCube® (imaGenes, Berlin,
Germany), amplified and subcloned into pcDNA-3.1. The
reading frame, PCR integrity of the cloned constructs and the
sequences of the mutants were confirmed by DNA sequencing.
Finally, amino-acid residues along the human M3R sequence
were numbered according the most conserved residue in the
TMH and thus following the consensus-numbering scheme
described by Ballesteros et al. [20].
Borroto-Escuela/Romero-Fernandez/García-Negredo/Correia/Garriga/
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Cell culture and transfection
COS-7 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum (FCS),
100 U/ml streptomycin, 100 µg/ml penicillin, 2 mM L-glutamine
(all from Invitrogen) at 37°C in a humidified 5% CO2 incubator.
For transfection, 2×106 cells were seeded into 100-mm dishes.
About 24 h later, cells were co-transfected with pcDNA3.1-
3xHA-M3R vector or mutants, by using the LipofectamineTM
Plus reagent (Invitrogen).
RNA Interference and immunofluorecence analysis
A pool of six different double-stranded siRNAs targeting
ARF-1 were designed by and obtained from Santa Cruz Bio-
technology (sc-141186, Stockholm, Sweden) and Selleck (ARF1
siRNA kit, TX, USA). A siRNA duplex with an irrelevant se-
quence (siRNA negative control, Selleck, TX, USA) was used
as a control. Thus, COS-7 cells were transfected with 20 µM
siRNA using Oligofectamine (Invitrogen) according to the
manufacturer’s instructions and transfection was repeated 24h
later. Then, the next day cells were challenged with CCh at the
indicated times and processed for ARF1 immunostaining and
PLD activity determinations. In brief, for ARF1 immunostaining
cells were labelled with the rabbit anti-ARF1 monoclonal anti-
body (Abcam, Stockholm, Sweden) and then a secondary anti-
rabbit antibody coupled to Alexa-Fluor 488 (Molecular Probe,
Stockholm, Sweden). Immunofluorescence analysis was car-
ried out by using a 63× oil immersion objective in a Leica TCS-
SL confocal microscope (Leica, USA). Images obtained from
ten cells (two different experiments) were analyzed for each
condition (control and ARF-1 depleted cells in 0, 15, 30 min
CCh treated cells). For each image the average fluorescence
intensity per field was examined.
Membrane preparation and radioligand binding assay
About 48 h after transfection, COS-7 cells were washed
twice with cold phosphate-buffered saline (PBS; pH 7.4),
harvested and homogenized in binding buffer (25 mM sodium
phosphate, 5 mM MgCl2, pH 7.4), using a Polytron tissue
homogeniser. Cell membranes were collected by centrifugation
at 20000xg for 15 min and homogenized as above. After
centrifugation at 40000xg for 20 min at 4°C, the final pellet was
resuspended in binding buffer, and membranes were either used
immediately or frozen in liquid nitrogen and stored at -80°C
until needed. Protein concentration was determined by using
the Bradford protein assay kit (Bio-Rad, Hercules, CA, USA).
To determine the affinity of NMS for each sample, membranes
were incubated with different concentrations of [3H]-NMS
(ranging from 12.5 pM to 1.5 nM) in binding buffer at 25°C for
60 min. Incubations were stopped by filtration through
Whatman (Maidstone, Kent, UK) GF/B filters and washed
extensively with ice-cold PBS before scintillation counting.
Nonspecific binding was determined in the presence of 10 µM
atropine. Agonist binding potencies were determined by means
of competition with [3H]-NMS. Briefly, membranes were
incubated with 0.1 nM [3H]-NMS and concentrations ranging
from 10 pM to 10 mM of CCh in binding buffer at 25°C for 3h.
Agonist binding studies were carried out without GTP and
GTP analogues; because previous studies had shown that such
agents did not affect the agonist binding properties of the M3R
when transiently expressed in COS-7 cells [21]. Assays were
stopped by filtration and samples were subject to scintillation
counting, as described above.
PLD and PLC assay activities
PLD and PLC activities were recorded as accumulation of
[3H]phosphatidylbutanol ([3H]PtdBut) and [3H]inositol
phosphate ([3H]IP), respectively [22]. Briefly, transfected COS-
7 cells growing in 12-well plates were metabolically labeled
with [3H]palmitate (2 µCi/well, Amersham Biosciences) and
[3H]myoinositol (3 µCi/ml, Amersham Biosciences) in inositol-
free DMEM (Invitrogen) during 18-24 h. For [3H]IP
determinations agonist (CCh) response were measured usually
over 40-60 min in the presence of 10 mM LiCl before cells were
lysed in ice-cold 10 mM formic acid. [3H]IP was separated on
Dowex AG1-X8 ion exchange columns (Bio-Rad, Hercules, CA,
USA). For [3H]PtdBut determinations agonist (CCh) response
was measured usually over 30-40 min in the presence of 30 mM
butan-1-ol, then phospholipids were extracted into chloroform/
methanol and [3H]PtdBut was separated on Whatman LK5D
thin layer chromatography plates (Whatman). For
desensitization experiments, in both assays, prelabeled cells
were treated 2 min with agonist in Hank’s Buffered Salt Solution
(HBSS), and then washed twice with HBSS (15 mM HEPES, 118
mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5Mm D-
glucose, pH 7.4). Then, agonist was added in the conditions
described above for the indicated periods of time. Inhibitory
agents and the butan-1-ol were added 30 min before and
immediately after agonist addition, respectively. For assays in
acute permeabilized cells, prelabeled COS-7 cells were incubated
with agonist (100 µM CCh) or vehicle for 10 min at 37°C before
intracellular buffer was added (2 mM MgATP, 10 µM NAD, 8
µM digitonin, and 30 mM butan-1-ol) in the presence or absence
of Brefeldin A (BFA) or C3 exoenzyme (C3). Data from
scintillation counting of 4 to 6 independent experiments were
expressed as means ± S.E.
When indicated, PLD activity was also evaluated by the
Amplex Red Phospholipase D assay kit (Molecular Probes,
Stockholm, Sweden) used according to the manufacturer’s
instructions. Briefly, transiently transfected COS-7 cells were
washed 3 times with phosphate-buffered saline and then
incubated overnight in basal medium containing 5 mg/mL
bovine serum albumin (BSA) and antibiotics. Cells were
challenged with CCh (10 µM) during 15 and 30 min. The basal
level of constitutive PLD activity was determined in the absence
of CCh. Next, cells were washed with and kept in 300 µL with
ice-cold 50 mM Tris, pH 8.0, containing 1 mM EGTA and
complete protease inhibitor cocktail without ethylenediamine-
tetraacetic acid (Roche, Stockholm, Sweden). Cells were lysed
by 3 freeze-thaw cycles, collected and mixed 1:1 (v/v) with
Amplex Red reaction buffer (Amplex Red Phospholipase D
assay kit; Molecular Probes), and PLD activity was measured
as a fluorescence signal after 30 minutes incubation at 37°C in
a POLARstar Optima plate reader (BMG Labtech, Offenburg,
Germany).
The M3R NPxxY Motif Cell Physiol Biochem 2011;28:1009-1022
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[35S]-GTPγS binding assay
COS-7 cell membranes were diluted in an ice-cold buffer
containing 10 mM HEPES and 0.1 mM EDTA, 5 Mm
deoxycholate, pH 7.4. Samples were subsequently pelleted and
resuspended in a binding buffer consisting of 10 mM HEPES,
10 mM MgCl2, 100 mM NaCl, pH 7.4 at a final protein
concentration of 125 µg/ml. Incubations were conducted in a
final assay volume of 1 ml (125 µg total protein) for 1 h at 30°C
in the presence of 1 µM GDP and 0.3 nM [35S]-GTPγS
(Amersham Biosciences) and the suitable ligand concentration
(CCh from 1 nM to 1 mM). The reaction was stopped by addition
of 5 ml of ice-cold buffer containing 10 mM HEPES/NaOH, 1 mM
MgCl2, pH 7.4 followed by rapid filtration through glass fibre
filters GF/C filters (Whatman) presoaked in the same buffer.
The filters were washed twice with 5 ml of ice-cold buffer and
the radioactivity was measured by scintillation counting.
Nonspecific binding was determined in the presence of 10 µM
GTPγS. Assays were performed in triplicate.
Co-immunoprecipitation and Western blot experiments
Immunoprecipitation and western blot experiments were
carried out as described previously [23]. Briefly, to
immunoprecipitate M3R constructs and its associated proteins,
plasmids encoding the 3xHA-M3R constructs and the Gαq/11,
Gα12/13, RhoAGFP, ARF1GFP or ARF6GFP expressing vectors were
transiently co-transfected into COS-7 cells. After 48 h cells
were serum-deprived for 4 h and then incubated in the absence
or presence of 10 µM of CCh for 10 min. After a washing with
cold PBS the cells were solubilized with 4 mM CHAPS and
processed for immunoprecipitation using a mouse anti-HA
monoclonal antibody (A01244, 1 µg; Genscript, Hong Kong).
Proteins transferred onto PVDF membranes were
immunodetected by using a goat anti-HA polyclonal antibody
(A00168, 1:1000; Genscript), rabbit anti-Gαq/11 polyclonal
antibody (sc-392, 1:1000; Santa Cruz Biotechnology), rabbit
anti-Gα12/13 polyclonal antibody (s-20, 1:300; Santa Cruz
Biotechnology) and rabbit anti-GFP polyclonal antibody
(A01388, 1: 10000; Genscript) as primary antibodies; and then
horseradish-peroxidase (HRP)-conjugated goat anti-rabbit IgG
(1:60000; Pierce, Rockford, IL, USA) and horseradish-
peroxidase (HRP)-conjugated mouse anti-goat IgG (1:30000;
Pierce) as secondary antibodies, and developed using
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
MAPK assay
Transiently transfected COS-7 cells expressing M3R
subtype were grown to 80% confluence and rendered quiescent
by serum starvation overnight before MAPK phosphorylation
assay. Subsequently, further 2h incubation in fresh serum-free
medium was performed to minimize basal activity. Then, cells
were stimulated by adding medium containing the muscarinic
agonist CCh (10 µM). Rapid rinsing, with ice-cold PBS finished
stimulation, and cell lyses was performed during 10 min by
adding 500 µl ice-cold lyses buffer (50 mM Tris-HCL, pH 7.4,
150 mM NaCl, 1% TritonX-100, protease and phosphatase
inhibitor cocktail). The cellular debris was removed by
centrifugation at 13000xg for 5 min at 4°C, and the total protein
content was measured using BCA Protein Assay Reagent
(Pierce). Aliquots corresponding to 5 µg of protein were mixed
with sodium dodecyl sulphate (SDS) loading buffer, applied to
12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
analyzed by Western blot. Extracellular signal regulated kinase
1/2 (ERK1/2) activation was assayed by incubating PVDF blots
with a mouse anti-phospho-ERK1/2 monoclonal antibody
(Sigma-Aldrich). Control blots were also run in parallel and
probed with rabbit anti-ERK1/2 polyclonal antibody (Sigma-
Aldrich) that recognized both unphosphorylated and
phosphorylated forms. The immunoreactive bands were
visualized as described above and then measured by
quantitative densitometry.
Data analysis
All binding data were analyzed using the GraphPad
PRISM 4.0 software (GraphPad Prism, San Diego, CA, USA).
Basal binding was defined as [35S]-GTPγS binding without
agonist in the [35S]-GTPγS binding assay. For each agonist
concentration, the percentage of binding over basal was
calculated to find out the agonist-stimulated [35S]-GTPγS
binding. Data were fit to a sigmoidal dose-response curve. For
statistical evaluation of the biochemical data, unless otherwise
mentioned, one-way analysis of variance (ANOVA) was used.
Group differences after significant ANOVAs were measured by
post hoc Bonferroni´s Multiple Comparison test.
Results
In order to unravel the structural and functional role
of the M3R NPxxY motif we performed mutagenesis
experiments. Thus, the Asn of this conserved domain
along muscarinic acetylcholine receptors (Fig. 1) was
replaced by aspartic acid (Asp; N7.49D) and by alanine
(Ala; N7.49A). Subsequently, agonist and antagonist
binding determinations, phosphoinositide hydrolysis
stimulation, G protein activation and co-
immunoprecipitation experiments with monomeric small
and heterotrimeric G proteins were performed after
transient expression of these receptor constructs into
COS-7 cells.
Ligand binding properties of the NPxxY motif
mutants
M3R
wt, M3R
N7.49D and M3R
N7.49A were transiently
expressed in COS-7 cells and assayed for their ability to
bind receptor agonist and antagonist. The results of
radioligand binding experiments are summarized in Table
1. In brief, saturation binding experiments showed that
the M3R
N7.49D mutant was expressed at a density
comparable to that observed for the M3R
wt, however the
M3R
N7.49A mutant showed a four-fold reduction in the
maximum binding capacity (Bmax; Table 1). In addition, all
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receptor mutants displayed an affinity for the NMS
antagonist similar to that observed by M3R
wt (Table 1).
On the other hand, when the agonist binding parameters
were assessed the M3R
N7.49D showed similar affinity for
carbachol when compared with M3R
wt but the M3R
N7.49A
showed a ~7.6 fold-increment in affinity, thus suggesting
that the Asn→Ala substitution increases the affinity of
the receptor for carbachol.
The M3R
N7.49A is unable to activate the PLC, the
PLD and the MAPK pathway
Next, we explored the functionality of each receptor
mutant expressed in COS-7 cells by quantifying the
activation of the main signaling pathways activated by
the M3R, namely the PLC, the PLD and the MAPK
pathway [3]. M3R-mediated PLC stimulation has been
extensively described and constitutes one of the main
pathways activated by this muscarinic acetylcholine
receptor subtype after agonist challenge [24, 25]. In order
to assess the ability of wild type and mutant receptors to
activate the PLC-signaling cascade, we measured the
total inositol phosphates (IP) accumulation. As expected,
the M3R
wt stimulation produced a dose-dependent
accumulation of IP with an EC50 of 3.4±0.5 µM (Fig.
2A). Also, the M3R
N7.49D showed a similar dose-response
curve of IP accumulation (EC50=3.6±0.2 µM; Fig. 2A).
Interestingly, under similar experimental conditions no
significant agonist-mediated IP accumulation was
observed in cells expressing the M3R
N7.49A (Fig. 2A).
Although the most established M3R signaling
pathway is the pertussis toxin-insensitive activation of
PLC via the heterotrimeric Gαq/11 protein, PLD is also
strongly activated via both the Gαq/11 and Gα12/13 proteins
[26, 27]. We then studied the ability of the M3R
wt and the
mutant receptors to activate PLD as measured by the
formation of phosphatidylbutanol (PtdBut). Interestingly,
while the M3R
wt and the M3R
N7.49D had a similar pattern
of PLD activation (EC50=1.4±0.6 µM and 1.2±0.3 µM,
respectively) the M3R
N7.49A was unable to activate PLD
even when exposed to 1 mM of CCh (Fig. 2B). Finally,
to rule out that the measured EC50 and Emax changes were
due to changes in receptor density we plotted the negative
logarithm of EC50 vs. the M3R
wt and M3R
N7.49D density.
This plot showed that while the receptor expression could
be slightly variable the EC50 shift was independent of
receptor density (data not shown).
The M3R NPxxY Motif
Table 1. Ligand binding properties of M3R constructs*.
*Radioligand binding studies on COS-7 cell membranes
expressing wild type M3R (3xHA-M3R
wt) or M3R mutants (3xHA-
M3R
N7.49D and 3xHA-M3R
N7.49A) were carried out as described
under Materials and methods. Curves were better fitted by
non-linear regression analysis assuming a single binding site.
KD values were determined by using GraphPad Prism software.
Kapp values were calculated from IC50 values using Cheng and
Prussof equation and can be consider an estimation of Ki values.
Hill coefficients (nH) was significantly smaller than 1 (P< 0.05).
¶p<0.05 when compared to COS-7 cells expressing 3xHA-M3R
wt
or 3xHA-M3R
N7.49D. Results represent mean ± S.E. (n = 5).
Fig. 1. Location of the NPxxY motif in the M3R helix net
representation. A. Schematic two-dimensional model of the
human M3R. The extracellular domain is located on top and the
intracellular domain at the bottom. The extracellular (E) and
intracellular (I) loops together with the putative juxtamembrane
helix 8 (HX8) are shown. Also, the mutated residue (N7.49)
within the NPxxY motif is highlighted (grey filled encircled
residue). Finally, the putative extracellular disulfide bond and
the glycosylation and palmitoylation sites are also depicted. B.
Schematic representation of the multiple alignments of the
NPxxY motif of the human muscarinic acetylcholine receptor
family (ACM1 to ACM5) and bovine rhodopsin (OPSD).
Residues that form part of the NPxxY motif at the end of TMH7
(blue cylinder) are shown in a grey filled box. The arrow denotes
the position of the Asn-7.49 within the NPxxY motif. Also, the
conserved residues among the family are depicted with an
asterisk and the putative HX8 is also shown (red cylinder).
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Next, we decided to test whether the M3R mutations
impinge into the receptor-mediated MAPK pathway
activation. It is well-known that M3R can activate the
MAPK pathway by two ways one that is dependent of
protein kinase C and the other independent [28, 29]. Thus,
we first assessed whether the M3R
wt transiently
expressed in COS-7 cells was able to activate MAPK in
response to CCh. A time course analysis of M3R
wt-
mediated ERK1/2 phosphorylation using 10 µM CCh
reveals a maximal activation at 5 min. Therefore, under
these experimental conditions we analyzed all M3R
construct. Interestingly, while the M3R
wt and the
Borroto-Escuela/Romero-Fernandez/García-Negredo/Correia/Garriga/
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Fig. 2. Activation of PLC and PLD by M3R constructs in COS-
7 cells. COS-7 cells were transiently transfected with the cDNAs
encoding M3R
wt (?), M3RN7.49D (?) and M3RN7.49A (?) and the
IP (A) and PtdBut (B) accumulation after stimulation with
increasing concentrations of CCh was determined as described
in Materials and Methods. Data are presented as an increase in
IP and PtdBut above basal levels in the presence of CCh and
referred to the maximal activation produced by M3R
wt. Basal
levels observed with the various receptor constructs were not
significantly different. Data represents the average ± S.E.M.
values of triplicate determinations of three independent
experiments.
Fig. 3. Stimulation of ERK1/2 by M3R constructs in COS-7
cells. COS-7 cells were transiently transfected with the cDNAs
encoding M3R
wr, M3R
N7.49D and M3R
N7.49A and serum deprived
for 12 h before adding CCh (10 µM) for 5 min. Then, cells were
washed and processed for MAPK phosphorylation assay (see
Materials and Methods). Unphosphorylated and
phosphorylated p42 and p44 MAPKs forms were detected
using a rabbit anti-ERK1/2 polyclonal antibody and a mouse
anti-phospho-ERK1/2 monoclonal antibody, respectively.
Immunoreactive proteins were detected using a horseradish
peroxidase-conjugated secondary antibody and enhanced
chemiluminescences. The intensity of the bands was quantified
using Imagen Quand Program (top). Bars represent the means
± S.E.M. of phosphorylated ERK1/2 (P-ERK1/2) normalized
using ERK1/2 and expressed as the percentage of change over
the M3R
wt level. Results were calculated from five separate
experiments. **p<0.001 when compared to unstimulated M3R
wt.
RDS, relative densitometric scanning.
M3R
N7.49D were able to induce a clear and consistent
ERK1/2 phosphorylation the M3R
N7.49A was unable to
trigger a significant ERK1/2 phosphorylation when
compared to the other two constructs (Fig. 3).
The M3R
N7.49A couples to but do not activate
Gαq/11
One intriguing question stills the fact that M3R
N7.49A
was unable to activate PLC and PLD. Previous studies
demonstrated that M3R activates PLC mainly via a Gαq/
11 and PLD via a Gα12/13 [27]. Thus, it might be the case
that this construct have a lesser affinity for G proteins
and when transiently expressed in COS-7 cells it is unable
to couple/activate the endogenous G proteins.
Consequently, we proceed to coexpress our M3R
constructs with Gαq/11 and Gα12/13 in COS-7 cells and
check for their functionality. In our hands, co-expression
of both Gαq/11 or Gα12/13 subunits with the M3Rwt and
the M3R
N7.49D increased [3H]IP and [3H]-PtdBut
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accumulation in a concentration dependent manner and
that reached a maximum when cells were transfected
with 5 µg of the respective Gα DNA plasmids. Under
these experimental conditions, when the M3R
N7.49A was
co-expressed with either Gα subunits we did not observed
PLC nor PLD activation, in agreement with our previous
results (Fig. 2). Besides that the M3R
N7.49A did not activate
PLC and PLD we wanted to explore if this receptor
mutant was able to directly activate Gα proteins, thus
we proceeded to check basal guanine nucleotide
exchange, using a [35S]GTPγS assay. Therefore, COS-7
cells were transiently transfected with the M3R
wt, the
M3R
N7.49D and the M3R
N7.49A and challenged with 10 µM
of CCh. Interestingly, while in cells transfected with the
M3R
wt and the M3R
N7.49D the agonist challenge induced a
clear increase in [35S]GTPγS binding (~43% over basal
for all two constructs) in the cells transfected with the
M3R
N7.49A no change in [35S]GTPγS binding was observed
after CCh challenge. Thus, these results clearly
demonstrated that the M3R
N7.49A is unable to activate both
endogenous and overexpressed Gα proteins.
Finally, in order to elucidate if the lack of M3R
N7.49A-
mediated Gα protein activation was due to the loss of
receptor-Gα protein interaction we performed co-
The M3R NPxxY Motif
Fig. 4. Asociation of M3R constructs with Gαq/11, Gα12/13, RhoA,
ARF1 and ARF6 proteins. COS-7 cells were transiently
transfected with the cDNAs (1 µg) encoding the untagged
GPR37 receptor (Mock), 3xHA-M3Rwt, 3xHA-M3RN7.49D and
3xHA-M3RN7.49A plus Gαq/11, Gα12/13, RhoAGFP, ARF1GFP or
ARF6GFP. Cells were incubated in the absence or presence of 10
µM of CCh for 10 min, solubilized and immunoprecipitated with
a mouse anti-HA monoclonal antibody (see Materials and
Methods). The immunoprecipitates were subjected to SDS-
PAGE and Western blotting analysis using goat anti-HA
polyclonal antibody, rabbit anti-Gαq/11 polyclonal antibody,
rabbit anti-Gα12/13 polyclonal antibody, and rabbit anti-GFP
polyclonal antibody to detect RhoAGFP, ARF1GFP and ARF6GFP.
Similar qualitative results were obtained in four independent
experiments.
Fig. 5. Characterization of agonist-mediated PLC and PLD
activation in COS-7 cells expressing M3R
wt and M3R
N7.49D. COS-
7 cells transiently transfected with the cDNAs encoding M3R
wt
and M3R
N7.49D were stimulated with 10 µM CCh during 10 min in
the absence (Control) or the presence of a Gβγ subunit inhibitory
peptide (co-transfection with plasmid pREP4-GRK2-Ct), U73122
(15 µM), brefeldin A (BFA, 100 µM) and C3 exoenzyme (C3, 4-8
µg/ml) as described in Materials and methods. The IP (A) and
PtdBut (B) accumulations were determined as described in
above. In control and inhibitor-treated cells, empty vector
equivalent to that used for pREP4-GRK2-Ct was contransfected
with the receptor constructs. Values are mean ± S.E.M. (n=5).
*p<0.05.
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immunoprecipitation experiments in COS-7
cells coexpressing the M3R
wt, the M3R
N7.49D and the
M3R
N7.49A together with Gαq/11 and Gα12/13. Thus, in cells
cotransfected with the M3R
wt and Gαq/11 the agonist
Borroto-Escuela/Romero-Fernandez/García-Negredo/Correia/Garriga/
Fuxe/Ciruela
Fig. 6. The M3R-mediated PLD activation is markedly impaired
in ARF1-depleted COS-7 cells. A. COS-7 cells were transfected
with M3R (1 µg) together with a pool of ARF1 siRNA or siRNA
negative control (20 µM). 48 hours after transfections cells
were serum-starved for 1 h and incubated in presence or absence
of CCh (10 µM) for the indicated time. Cells were then fixed and
processed for ARF1 immunostaining (see Materials and
Methods). Distribution in the control and ARF-1 siRNA
transfected cells was examined by confocal microscopy. Left
panel illustrates the plasma membrane/cytosolic distribution
of the ARF-1 before and after agonist-activation; right panel
shows the reduction in the ARF-1 immunofluorescence in
ARF1-depleted cells before and after agonist incubation.
Arrows denote the plasma membrane distribution of ARF1.
This figure is representative of the results obtained in two
independent experiments. B. Quantitative ARF-1 immuno-
fluorescence defined as the average fluorescence intensity in
a constant field. The data represent the mean ± S.E. of 2
independent experiments (ten images). Statistical significance
was determined using Two way ANOVA (PRISM software) (***,
p < 0.001). C. Agonist-induced PLD activation in control or
ARF1-depleted COS-7 cells. Cells, transiently expressing the
M3R, were treated with 10 µM of CCh for 15 and 30 min. The
data represent the mean ± S.E. of three independent experiments.
Statistical significance was determined using Two way ANOVA
(PRISM software) (***, p < 0.001).
Fig. 7. Characterization of M3Rwt- and M3RN7.49D-mediated PLD
and PLC activation/desensitization. A. PLC activation/
desensitization time-course. COS-7 cells were transiently
transfected with M3Rwt (?) and M3RN7.49D (?) and the [3H]IP
accumulation after CCh (10 µM) challenge was measured at
different activation time points (left panel). In addition, cells
were pretreated (desensitized) for 2 min with 1 mM CCh (right
panel). After washing the cells, a second agonist challenge (10
µM CCh) at the indicated time was performed and the induced
[3H]IP accumulation was measured (see Materials and
Methods). Values are expressed as fold over basal (mean ±
S.E.M. performed in triplicate) of four to six independent
experiments. B. PLD activation/desensitization time-course.
COS-7 cells were transiently transfected as in panel A and the
[3H]PtdButP accumulation after CCh (1 mM) challenge was
measured at different activation time points (left panel). In
addition, cells were pretreated (desensitized) for 2 min with
1mM CCh (right panel). After washing the cells, a second
agonist challenge (10 µM CCh) at the indicated time was
performed and the induced [3H]PtdButP accumulation was
measured (see Materials and methods). Values are expressed
as fold over basal (mean ± S.E.M. performed in triplicate) of
four to six independent experiments.
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challenge (10 µM of CCh) promoted the interaction
of the receptor with the G protein as a band that
migrated at 42 kDa corresponding to the Gαq/11 was
clearly coimmunoprecipitated using an antibody against
the receptor (Fig. 4). Interestingly, when the
M3R
N7.49D and the M3R
N7.49A were immunoprecipitated
after agonist treatment it was clear that Gαq/11 was
coimmunoprecipitated with these two receptor
constructs. These results show that the M3R
N7.49A binds
Gαq/11 after agonist challenge. Subsequently, similar
experiments were performed to check the receptor
association with Gα12/13. A faint basal association of
the M3R
wt and the M3R
N7.49D to the Gα12/13 was observed
(Fig. 4). Interestingly, this basal association with the
Gα12/13 protein was unaltered by agonist challenge in the
cells expressing the M3R
wt but was increased (~5 fold
over the basal) in the cells transfected with the
M3R
N7.49D and challenged with CCh (Fig. 4). Under these
experimental conditions the M3R
N7.49A did not show
any association with the Gα12/13 even after agonist
challenge (Fig. 4). Overall, these results demonstrated
that the M3R
N7.49A associated with Gαq/11 in a similar way
as to the M3R
wt, however this association was
not sufficient to activate it, thus suggesting that Asn-7.49
is specifically involved in the M3R-mediated Gαq/11
protein activation. Also, the Asn→Asp substitution
within the NPxxY promoted the association of M3R
wt
to Gα12/13.
The Asn-7.49 plays a key role in the agonist-
mediated receptor association with and signals
by small monomeric G proteins
In order to elucidate the role of Asn-7.49 in the
mechanism of M3R signaling through small monomeric
G proteins we performed coimmunoprecipitation
experiments with the ARF and RhoA proteins as these
have been described to partake in the receptor signal
transduction [16, 18, 19, 30]. Consequently, in cells
cotransfected with the M3R
wt and RhoAGFP the agonist
challenge promoted the receptor-RhoA interaction as a
band that migrated at 50 kDa corresponding to the
RhoAGFP was coimmunoprecipitated using an antibody
against the HA tag present in all the M3R constructs (Fig.
4). Interestingly, while the M3R
N7.49D was also able to
interact with RhoA after agonist challenge the M3R
N7.49A
did not show association with RhoA, thus corroborating
again the ineffectiveness of M3R
N7.49A to couple to the
canonical Gα12/13/Rho signaling pathway. Subsequently,
similar coimmunprecipitation experiments were performed
with ARFs proteins. Thus, in cells cotransfected with the
M3R
wt and ARF1 the agonist challenge promoted a
significant receptor-ARF1 association that was not
observed with either the M3R
N7.49D or M3R
N7.49A (Fig. 4).
Interestingly, in cells cotransfected with the M3R
wt, the
M3R
N7.49D and the M3R
N7.49A plus ARF6 the agonist
treatment was unable to promote the association of these
receptor constructs with ARF6 (Fig. 4). Finally, no co-
The M3R NPxxY Motif
Fig. 8. Schematic representation of the proposed role of the Asn-7.49 in the M3R signalling complex formation. The signal
transduction complex associated with the M3R, which contains the NPxxY motif, is shown. The receptor modulates PLD activity
mainly by the Gαq/11/ARF1/RhoA/βγ subunit signaling complex, thus a fast activation and desensitization of PLD might be
achieved after CCh challenge.
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immunoprecipitation of these small G proteins was
observed when an HA untagged GPR37 receptor was
used in our experiments as a control (Fig. 4, Mock).
Collectively, our coimmunoprecipitation experiments
allowed us to show that ARF1 and ARF6 are constitutively
associated with the M3R and that the carbachol challenge
promoted the coupling of RhoA and ARF1 with the
receptor. Overall, it can be concluded that ARF1 is
switched to Gα12/13 as NPxxY is mutated to DPxxY.
Next, we pharmacologically characterized the
agonist-mediated PLC and PLD activation in COS-7 cells
expressing M3Rwt and M3RN7.49D by means of a panel of
specific inhibitors. Thus, the M3Rwt and the M3RN7.49D-
mediated PLC activation was equally blocked by the
U73122, an inhibitor of PLC-dependent processes [31]
(Fig. 5A). Interestingly, the M3Rwt and the M3RN7.49D-
mediated PLC activation was not inhibited by brefeldin A
(BFA), an inhibitor of guanine-nucleotide exchange in
ARF [32]; by C3 exoenzyme from Clostridium
botulinum which inactivates Rho family members (i.e.
RhoA) by means of covalent ADP-ribosylation [33]; and
by coexpression with the C-terminal tail of the GRK2,
which acts as G protein βγ-subunit scavenger [34] (Fig.
5A). These results demonstrated that the Asn→Asp
substitution at the conserved NPxxY motif do not affect
the PLC activation pattern. On the other hand, M3Rwt-
mediated PLD activation was sensible to BFA, to C3
exoenzyme and to the inhibitory G protein βγ peptide (Fig.
5B). These results suggest that the small G proteins (e.g.
ARF1/6 and RhoA) and the G protein subunits βγ are
involved in the PLD activation, thus illustrating a cross-
talk between heterotrimeric and monomeric G-proteins.
Interestingly, the M3R
N7.49D-mediated PLD activation was
not blocked by either BFA, C3 exoenzyme or the inhibitory
G protein βγ peptide (Fig. 5B), thus suggesting that the
Asn-7.49 play a key role in the ARF/Rho/βγ subunit-
mediated PLD activation. Overall, these results agree
with the current notion that during agonist activation the
M3R suffers a conformation change that allows the
selective translocation/activation of ARF1/RhoA/βγ
subunit to the plasma membrane and thus promoting the
activation of PLD and controling the PLD desensitization
process.
To further confirm the role of ARF1 in the M3R-
mediated PLD activation, we studied PLD activity in
ARF1-deficient cells. To this end, a pool of six different
double-stranded siRNAs targeting ARF-1 was used to
knock down the ARF1 expression in COS-7 cells. Firstly,
by means of immunofluorescence and confocal miscro-
scopy observations we confirmed that the transfection
Borroto-Escuela/Romero-Fernandez/García-Negredo/Correia/Garriga/
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of the ARF1 siRNA, but not the control siRNA, largely
reduced (~85%) the ARF1 expression in COS-7 cells
(Fig. 6A-B). In addition, when the subcellular distribution
of ARF1 was analyzed in control cells (transfected with
the control siRNA) we found mostly a cytosolic distribution
of the ARF-1 protein that was almost undetectable in
ARF1 siRNA transfected cells (Fig. 6A). Interestingly,
when cells were challenge with CCh the ARF1 protein
showed a more plasma membrane/cytosolic subcellular
distribution (Fig. 6A) which again was almost undetectable
in cells transfected with ARF1 siRNA (Fig. 6A). In
addition, it is noticeable that CCh incubation promoted a
marked change in the cellular shape, probably as result
of a cell cytoskeleton rearrangement (Fig. 6A), as it has
been previously demonstrated [35]. Indeed, a canonical
Rho-mediated cytoskeletal rearrangement has been
described [36]. Next, under these experimental conditions
(i.e. ARF-1 siRNA transfection) we assessed the ability
M3R to activate PLD after agonist challenge. Thus,
transiently transfect COS-7 cells were incubated with 10
µM CCh for 15 and 30 min and the PLD activity
measured. Interestingly, the activation of PLD following
CCh stimulation was dramatically reduced in the cells
cotransfected with the ARF-1 siRNA (Fig. 6C). However,
when cells were cotransfected with the control siRNA a
significant increased in the PLD activity was observed
after 15 and 30 min of CCh incubation (Fig. 6C). Overall,
these data further support the idea that ARF1, probably
at the plasma membrane, specifically regulates M3R-
mediated PLD activation.
The M3R
N7.49D displays an unlike PLD activation
time-course and desensitization profile
The agonist challenge of the M3R activates both PLC
and PLD by means of different molecular mechanisms
and time kinetics [3], thus, we decided to study the PLC/
PLD activation time-course and desensitization profile
for the M3R
wt and the M3R
N7.49D. Initially, experiments
of time-course activation of PLC showed that the M3R
wt
and the M3R
N7.49D shared a similar PLC activating profile
after CCh challenge (Fig. 7A, left panel). It is important
to mention here that the time-course of CCh-stimulated
IP accumulation in cells expressing the M3R
wt and the
M3R
N7.49D reached a peak around 40 minutes after agonist
exposure. On the other hand, a 2 min preexposure of the
M3R
wt and the M3R
N7.49D to 1 mM of CCh induced an
acute sensitization of the receptor-mediated PLC
activation (~6 fold over the basal after 1 hour of the initial
2 min agonist challenge), as previously described in HEK
cells [22]. Overall, no obvious differences in the PLC
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activation time-course and desensitization profile between
the M3Rwt and the M3RN7.49D were observed.
Next, we performed time-course experiments of
receptor-mediated PLD activation. Thus, the M3Rwt
showed a pattern of PLD activation with a maximal peak
after ~5 min of agonist incubation, followed by a stable
plateau (Fig. 7B, left panel). Interestingly, the M3RN7.49D
showed an unlike PLD activation profile that was more
similar to that observed for the activation of PLC, thus
reaching a maximal peak between 40 to 60 minutes after
agonist exposure (Fig. 7B, left panel). On the other hand,
a 2 min agonist preexposure of the M3Rwt induced a rapid
and persistent desensitization of the receptor-mediated
PLD activation (Fig. 7B, right panel), as previously
described [22]. Interestingly, the M3RN7.49D showed a PLD
desensitization profile more similar to the one observed
for the PLC, thus the 2 min agonist preexposure induced
an acute sensitization of the receptor-mediated PLD
activation (~4 fold over the basal after 30 min) (Fig. 7B,
right panel). These results indicate that there are
differences in the kinetics of the receptor-mediated PLD
activation/desensitization between the M3RN7.49D and the
M3Rwt. However, there is not a clear explanation for these
differences. Thus, the M3RN7.49D-mediated PLD
activation pattern resembles the one observed for the
receptor-mediated PLC activation/desensitization.
Interestingly, as the M3RN7.49D lacks the carbachol-
mediated receptor-ARF1 association it could be proposed
that the fast activation and fast desensitization of the M3R-
mediated PLD activation is ARF1 dependent (Fig. 8).
Therefore, it might be speculated that M3R
wt can activate
PLC and PLD through a signaling complex (e.g. Gαq/11/
Gα12/13/ARF1/RhoA/βγ subunit) that might be different
to that used by the M3R
N7.49D. Overall, the Asn→Asp
substitution at the conserved NPxxY motif determines
the receptor-G protein switching mode and specificity of
the effector activation (e.g. PLC and PLD).
Discussion
Sequence alignment of class A GPCRs reveals that
most of its members contain the NPxxY motif [37].
Interestingly, mutagenesis experiments along this domain
have been shown to affect the receptor’s ligand affinity,
expression, G protein-coupling, association with small G
proteins and endocytosis [10-13, 38]. As the M3R also
contains this NPxxY motif at the end of it seven
transmembrane domain (Fig. 1) we wanted to know the
precise role of this motif in receptor functioning.
Consequently, to address this question we used site direct
mutagenesis in combination with coimmunoprecipitation
experiments and signal transduction assays. Thus, this
study demonstrates for the first time that the Asn-7.49 of
the M3R NPxxY motif plays a key role in the carbachol-
mediated ARF1 association and PLD activation.
Our results are in line with previous studies
demonstrating that some residues located within
transmembrane helix 7 of certain GPCRs while not being
directly implicated in ligand-binding they are involved in
the receptor signal transduction. Indeed, during the
agonist-mediated conformational rearrangement the
residues forming the NPxxY motif are key positions in
hydrogen bound formation through receptor stabilization
[12, 39, 40]. In our hands, in the M3R the Asn→Ala
substitution (N7.49A point mutation) resulted in a
significant decrease in the antagonist maximum binding
capacity and an increase in the agonist affinity. A potential
explanation would be that the nature of the
physicochemical change involved in Asn to Ala mutation
somehow affects the hydrogen bond formation essential
for keeping the receptor in a stable conformation during
activation. Interestingly, Ala replacement at position N7.49
in rhodopsin and in the formyl peptide receptor (FPR)
while not promoting a conformational reorganization of
the active state of the receptor it implicated a variable
change in agonist/antagonist affinity when compared to
the wild type receptor [10, 12]. On the other hand, the
M3R Asn→Asp substitution (N7.49D point mutation) did
not affect the agonist/antagonist binding properties of the
receptor, thus suggesting that this change in charge did
not affect the receptor ligand binding properties. In addition,
the N7.49A/D M3R mutants provided further information
concerning the receptor’s downstream signal transduction.
Thus, while the N7.49D point mutation did not affect the
affinity and efficacy of the receptor-mediated PLC and
PLD activation the N7.49A one precluded the receptor
to activate both phospholipases. A comparable functional
result was observed when the MAPK pathway was
analyzed, thus the M3R
N7.49A mutant was unable to elicit
a significant ERK1/2 phosphorylation. Overall, while the
change of Asn by Asp maintains a relatively stable
conformation of the receptor and does not substantially
perturb the conformational change produced during
receptor activation the Asn→Ala substitution precluded
the receptor-mediated signal transduction.
Our coimmunoprecipitation studies with monomeric
small and heterotrimeric G proteins grant some insight
about the M3R signal transduction mechanism. First, we
showed that M3R constitutively associated with Gq/11,
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ARF1 and ARF6 (Fig. 4) and that agonist challenge
promoted the coupling of Gαq/11, RhoA and ARF1 with
the receptor (Fig. 8). In addition, the M3Rwt-mediated
PLC activation was inhibited by U73122 and the PLD
activation by BFA, by C3 exoenzyme and by a G protein
βγ-subunit scavenger. Hence, a major signal transduction
complex containing Gαq/11, ARF1, RhoA and G proteinβγ-subunit was depicted (Fig. 8). Next, when the Asn-
7.49 of the M3R NPxxY motif was substituted for Ala
(N7.49A point mutation) despite a constitutive faint basal
association with ARF1/6 and an agonist-promoted
Gαq/11 coupling was observed the M3RN7.49A was unable
to associate to Gα12/13 and to RhoA, and thus to activate
both PLC and PLD. Finally, the Asn→Asp substitution
although did not affect the agonist-mediated receptor
association with Gαq/11 and RhoA it precluded the agonist-
mediated receptor-ARF1 association and favored the
Gα12/13 coupling. Interestingly, this unusual receptor
coupling pattern did not affect to the PLC activation but
it had a profound effect on the PLD stimulation, thus
being now insensitive to the G protein βγ-subunit scavenger
and to the monomeric small G proteins inhibitors (e.g.
BFA and C3 exoenzyme). In addition, our coimmunopreci-
pitation experiments clearly demonstrated that the N7.49D
mutant retains an intact capacity to form stable complexes
with RhoA in response to CCh (Fig. 4), thus the formation
of high affinity M3R-RhoA complexes is not sufficient to
activate PLD in a RhoA-dependent manner (Fig. 5B, right
panel), and consequently, it can be assumed that RhoA is
not involved in the M3R
N7.49D-mediated PLD activation.
Overall, the Asn-7.49 of the M3R NPxxY motif is
specifically involved in the CCh-mediated ARF1
association and in the RhoA-mediated PLD activation.
Previous studies reported that a N376 to D mutation
in the conserved NPxxY motif of the 5-HT2A receptor
alters the coupling preference from ARF1 to ARF6 [14,
41]. These data suggest that the presence of the N or a
D in this highly conserved motif is an important, but not
exclusive, determinant of which ARF isoform interacts
with the GPCR, since some NPxxY motif-containing
receptors such as the M3R used both isoforms. Our results
partially agree with these as the presence of Asp in the
M3R DPxxY motif did not promote the coupling to ARF6,
as happens for other receptors, but precluded the agonist-
mediated association with ARF1. Interestingly, it has been
nicely demonstrted that mutation of the Asn-7.49 of the
conserved NPxxY motif of the cholecystokinin B receptor
(CCKBR) abolishes Gαq/11 protein activation without
affecting its association with the receptor [11]. In brief,
the mutated CCKBR retains an intact capacity to form
stable complexes with Gαq/11 subunits in response to CCK
but it was completely unable to mediate activation of either
phospholipase C and protein kinase C-dependent and -
independent mitogen-activated protein kinase pathways
[11], thus indicating  that the formation of high affinity
CCK-receptor-Gαq/11 protein complexes is not sufficient
to activate Gαq/11 and suggest that while the Asn-7.49 is
specifically involved in Gαq/11 protein activation other
residues might be involved in Gαq/11binding [11]. Similarly,
we described here that the Asn→Asp substitution within
the M3R NPxxY motif did not affect the association with
RhoA but it precluded the small G protein-dependent PLD
activation, thus it can be hypothesized that either other
residues different than Asn-7.49 might participate in the
M3R-RhoA interaction or that other proteins that act as
adapters or regulators of small G protein function may
participate or mediate in the association with the receptor.
Thus, future studies devoted to clarify the nature of this
interaction will determine if RhoA and M3R interact
directly to activate RhoA or if the complex involves other
proteins (i.e. ARFs, etc.). Overall, we identified here a
single residue within the M3R sequence that appears to
act as a molecular switch for receptor-mediating RhoA
activation.
It has been shown that agonist challenge of the M3R
leads to activation of both PLC and PLD but with distinct
efficacies and stimulation/desensitization time-courses
[22]. However, the essential transducing elements
responsible for this differential stimulation/desensitization
pattern were not fully identified. Also, it has been demon-
strated that the M3R substantially used an ARF-dependent
pathway for PLD activation [30]. Thus, the M3R display-
ed a major ARF1-dependent route for PLD1 activation,
whereas the ARF6-dependent pathway activates both
PLD1 and PLD2 [30]. Nonetheless, the role of ARFs
proteins in the M3R-mediated desensitization of these
phospholipases has not been unraveled yet. Our results
demonstrated that the Asn-7.49 is essential for grip the
M3R-mediated PLD fast activation and long-lasting
desensitization observed in our experiments and also
previously reported [22]. This long-lasting M3R-mediated
PLD desensitization suggests that either an inhibitory factor
is formed upon receptor activation or that the activated
receptor induces the loss or permanent inactivation of an
essential coupling component. Indeed, our results also
suggest that the Asn-7.49 is necessary for the carbachol-
mediated ARF1-receptor association. Thus, we can
conclude that the M3R-mediated PLD fast activation and
long-lasting desensitization is ARF1 dependent (Fig. 8).
Finally, some members of the GPCR family receptors
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exchange the NPxxY motif by DPxxY in TM 7 (i.e. P2U
purinergic receptor, PAR, GnRH receptor, etc.) [42], a
fact that seems to confer a different pattern of small G
proteins activation [14]. Collectively, our results suggest
that NPxxY→DPxxY swapping in the M3R it switch the
receptor from one signaling complex (e.g. Gαq/11/ARF1/
RhoA/βγ subunit) to another (e.g. Gαq/11/Gα12/13/RhoA).
Interestingly, these signal transduction complexes have
different PLD activation time-course and desensitization
profile.
Abbreviations
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